期刊文献+

厄洛替尼单药治疗晚期非小细胞肺癌疗效与安全性评价 被引量:1

下载PDF
导出
摘要 选择18例晚期、复发的非小细胞肺癌(NSCLC)患者,给予厄洛替尼150 mg/d口服治疗,观察其疗效和不良反应。采用KPS评分对患者生活质量和临床症状进行评价;观察中位肿瘤进展时间(TTP)和中位生存时间(MST)。结果有效率22.2%,疾病控制率77.8%;随诊>12个月者7例,1 a生存率38.9%,TTP为5.6个月,MST为11.9个月;生活质量评分增加。主要不良反应为Ⅰ、Ⅱ度皮疹和腹泻,对症处理后可缓解。认为厄洛替尼单药对晚期NSCLC有明显抗肿瘤作用,能提高患者生活质量,改善临床症状,且不良反应轻微。
出处 《山东医药》 CAS 北大核心 2008年第42期76-77,共2页 Shandong Medical Journal
  • 相关文献

参考文献4

  • 1张菊,朱孝峰,刘宗潮.酪氨酸激酶小分子抑制剂在肿瘤治疗中的研究[J].国外医学(肿瘤学分册),2003,30(3):199-201. 被引量:10
  • 2De Jager J, Stebbing J. Erlofinib or capecitabine with gemcit-abine in pancreatic cance[J]. Future Oncol,2006,2(2) :161-163.
  • 3Lynch TJr, Kim E. Optimizing chemotherapy and targeted agent combinations in NSCLC [ J ]. Lung Cancer,2005,50 ( Suppl2 ) : S25-32.
  • 4Sridhar SS,Seymour L,Shepherd FA. Inhibitors of epidermal-growthfactor receptors: a review of clinical research with a focus on non-small cell lung cancer[J]. Lancet Oncol, 2003,4(7) :397-406.

二级参考文献2

共引文献9

同被引文献19

  • 1Parkin DM, Bray F, FerlayJ, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55(2): 74-108.
  • 2Yang L, Parkin DM, Li LD, et al. Estimation and projection of the national profile of cancer morality in China: 1991-2005. BrJ Cancer, 2004, 90(11): 2157-2166.
  • 3Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med, 2004, 25 (Snppl 1): 3-10.
  • 4American Cancer Society. Cancer facts and figures 2005. Available at: http://www.cancer.org/docroot/STT/stt_O.asp. Accessed October 20th 2006.
  • 5Smith J. Erlotinib: Small molecule targeted therapy in the treatment of nonsmall-cell lung cancer. Clinical Therapeutics, 2005, 27(10): 1513-1534.
  • 6Kosaka T, Yatabe Y, Endoh H, et al. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res, 2004, 64(24): 8919-8923.
  • 7Cohen MH,'Johnson JK, Chen YF, et al FDA drug approval summary: Erlotinib (Tarceva) tablets. Oncologist, 2005, 10(7): 461.
  • 8Juni P, Altman DG, Egger M. Assessing the quality of controlled clinical trials. BMJ, 2001, 323 (7303):42-46.
  • 9Shepherd FA, Rodrigues Pereira J, Ciuleanu T, a al. Erlotinib in previously treated non-small-celllung cancer. N EnglJ Med, 2005, 353(2): 123-132.
  • 10Lilenbaum R, Axelrod R, Thomas S, et al. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small- cell lung cancer and a performance status of2.J Clin Oncol, 2008, 26(6):.

引证文献1

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部